`
`Inventors: GURNEY el al.
`
`Confirmation No.: 7085
`
`Applicant: OncoMed Pharmaceuticals, Inc.
`
`Art Unit: 1643
`
`Application No.: 15/310,132
`
`Examiner: NATARAJAN, MEERA
`
`§ 371(c) Date: November 10, 2016
`
`Atty. Docket: 2293.1220001/PAC/E-H/M-S
`
`Title: IMMUNOTHERAPY WITH BINDING AGENTS
`
`First Supplemental Information Disclosure Statement
`
`Mail Stop Amendment
`
`Commissioner for Patents
`
`PO Box 1450
`
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Listed on accompanying IDS Forms PTO/SB/08b equivalent are documents that may be
`
`considered material to the patentability of this application as defined in 37 CPR. § 1.56, and in
`
`compliance with the duty of disclosure requirements of 37 CPR. §§ 1.97 and 1.98. The numbering
`
`on this First Supplemental Information Disclosure Statement is a continuation of the numbering in
`
`Applicant's Information Disclosure Statement filed on December 13, 2017 in connection with the
`
`above-captioned application.
`
`Where the publication date of a listed document does not provide a month of publication, the
`
`year of publication of the listed document is sufficiently earlier than the effective U.S. filing date
`
`and any foreign priority date so that the month of publication is not in issue. Applicant has listed
`
`publication dates on the attached IDS Forms based on information presently available to the
`
`undersigned. However, the listed publication dates should not be construed as an admission that the
`
`information was actually published on the date indicated.
`
`
`
`- 2 -
`
`GURNEY el al.
`
`Application No. 15/310,132
`
`Applicant reserves the right to establish the patentability of the claimed invention over any
`
`of the information provided herewith, and/or to prove that this information may not be prior art,
`
`and/or to prove that this information may not be enabling for the teachings purportedly offered.
`
`This statement should not be construed as a representation that a search has been made, or
`
`that information more material to the examination of the present patent application does not exist.
`
`The Examiner is specifically requested not to rely solely on the material submitted herewith.
`
`This is a filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statement is being
`
`before the mailing date of a first Office Action on the merits. No statement or fee is required.
`
`A copy of document NPL15 is submitted.
`
`It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS
`
`Forms, and indicate in the official file wrapper of this patent application that the documents have
`
`been considered.
`
`The US. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or
`
`credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & Fox P.L.L.C.
`
`/Erin J. Heenan/
`
`Erin J. Heenan
`
`Agent for Applicant
`Registration No. 70,012
`
`974436671docx
`
`Atty. Dkt. No. 2293 . 1220001/PAC/E-H/M-S
`
`Date:
`
`9/4/2018
`
`1100 New York Avenue, NW.
`Washington, DC. 20005-3934
`(202) 371-2600
`
`